Hoppa till huvudinnehåll

    Main navigation

    • Investerare
    • Om oss
    • Nyheter
    • Kontakta oss
    • Egoo.health
    • en
    • sv
Hem

Main navigation

  • Investerare
  • Om oss
  • Nyheter
  • Kontakta oss
  • Egoo.health
  • en
  • sv
 

Investerare

+

Main navigation

Main navigation

  • Nyheter - Pressmeddelande
  • Finansiell kalender
  • Finansiella rapporter
  • Bolagsstyrning
    • Bolagsordning
    • Bolagsstämmor
      • Årsstämma den 28 maj 2025
      • Extra bolagsstämma 21 Mars 2025
      • Extra bolagsstämma 8 Nov 2024
      • Årsstämma den 26 juni 2024
      • Extraordinary general meeting 23 April 2024
      • EXTRA BOLAGSSTÄMMA 16 JANUARI 2024
      • ÅRSSTÄMMA DEN 4 MAJ 2023
      • EXTRA BOLAGSSTÄMMA 24 MARS 2023
      • EXTRA BOLAGSSTÄMMA 27 SEPTEMBER 2022
      • ÅRSSTÄMMA DEN 5 MAJ 2022
      • Årsstämma den 5 maj 2021
      • Extra bolagsstämma 19 nov 2020
      • Extra bolagsstämma januari 2020
      • Årsstämma den 20 maj 2020
    • Revisor
    • Certified adviser
  • Aktieinformation
    • Aktiekapitalets utveckling
    • Incitamentsprogram
    • Utdelningspolicy
    • Företrädesemission 2022
    • FÖRETRÄDESEMISSION 2023
    • FÖRETRÄDESEMISSION 2024
    • FÖRETRÄDESEMISSION 2025
    • Teckningsoptioner (TO)
    • IPO och listning-dokument
  • Styrelse
  • Ledning
  • Insynspersoner
  • Analytiker
  • IR kontakt
  • Presentationer
regulatorisk
2025-05-07 09:01
Qlife Holding AB publicerar årsredovisning för 2024
Årsredovisningen kan laddas ner från hemsidan eller beställas från Qlife, info@egoo.health. För ytterligare information vänligen kontakta: Thomas Warthoe, VD Qlife Holding Epost: tw@egoo.health...
regulatorisk
2025-04-25 11:26
Kallelse till årsstämma 2025 i Qlife Holding AB
Rätt att delta och anmälan Den som önskar delta i stämman ska: dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende förhållanden på avstämningsdagen som...
icke regulatorisk
2025-04-10 13:00
Qlife announces strategic roadmap update
Qlife is a first mover in the growing market for at-home, lab-grade biomarker testing. The company’s strategic roadmap focuses on the following areas: Hospital-at-Home - China market Egoo Phe...
icke regulatorisk
2025-03-25 09:00
Qlife announces that it has received approval from UK authorities to initiate a clinical trial in the UK
The clinical trial will run for six months in the UK, after which the dossier will be submitted to the relevant UK authorities. As self-testing by non-professional users represents the highest...
regulatorisk
2025-03-21 10:32
Kommuniké från extra bolagsstämma i Qlife Holding AB den 21 mars 2025
Val och arvodering av styrelse  Stämman beslutade att omvälja styrelseledamöterna Lars Staal Wegner och Mikael Persson samt att välja Flemming Pedersen, Jørgen Drejer och Jacob Glenting som...
regulatorisk
2025-03-14 17:45
Qlife announces the last day of trading in BTA
The rights issue that was announced on 29 January 2025 (the “Rights Issue”) in Qlife Holding AB (publ) (“Qlife” or the “Company”) has been registered with the Swedish Companies Registration Office (...
regulatorisk
2025-03-05 11:31
Qlife carries out a directed issue to guarantors in connection with the completed rights issue and a directed issue of warrants to JEQ Capital AB
Qlife Holding AB (publ) (“Qlife” or the “Company”) has completed the issue of shares with preferential rights for the Company's shareholders that was resolved by the Board of Directors on 29 ...
icke regulatorisk
2025-03-04 10:45
Qlife reaffirms its strategy and plans to expand the Board with three new members
With approximately 91 percent subscription in the rights issue and a secured credit facility, Qlife has ensured financing for at least the next 12 months. The company is now able to solely focus on...
regulatorisk
2025-03-04 10:40
Kallelse till extra bolagsstämma i Qlife Holding AB
Rätt att delta och anmälan Den som önskar delta i stämman ska: dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende förhållanden på avstämningsdagen som...
regulatorisk
2025-02-26 19:27
Qlife announces outcome in rights issue
On 29 January 2025, Qlife Holding AB (“Qlife” or the “Company”) announced a rights issue of approximately SEK 11.8 million (the “Rights Issue”). The subscription period of the Rights Issue ended on...
regulatorisk
2025-02-21 10:00
The subscription period in Qlife’s rights issue ends on Tuesday, 25 February 2025
Tuesday, 25 February 2025, is the last day of the subscription period in Qlife Holding AB’s (“Qlife” or the “Company”) rights issue of approximately SEK 11.8 million (the “Rights Issue”). Please note...
icke regulatorisk
2025-02-21 09:00
Qlife has successfully verified the biomarkers related to the previously announced LOI
On 28 January 2025, Qlife signed a Letter of Intent (LOI) with a top-20 global pharmaceutical company to explore potential commercial collaborations. Among the key criteria outlined in the LOI was...
icke regulatorisk
2025-02-17 09:00
Qlife announces the launch of Egoo.AI and the start of sales for the Women’s Health platform
The newly introduced Women’s Health product covers key aspects of fertility, menopause, thyroid disease and Vitamin D, enabling users to track and understand hormonal changes that impact their...
regulatorisk
2025-02-14 09:00
Qlife launches Thyroid Disease and Vitamin D biomarkers, now available for immediate sales
The newly added biomarkers for Thyroid Disease and Vitamin D will be launched on the recently announced CE-IVD-marked platform, developed in collaboration with Hipro Biotechnology. With the addition...
regulatorisk
2025-02-12 08:00
Members of the Board of Directors and management intend to subscribe in the ongoing rights issue
The non-binding intention from the Board of Directors and management amounts to approximately 1.2 MSEK. In addition, Lars Bangsgaard is also participating in the top-down-guarantee that was...
regulatorisk
2025-02-11 08:00
The subscription period in Qlife’s rights issue begins today
Today, 11 February 2025, is the first day of the subscription period in Qlife Holding AB’s (“Qlife” or the “Company”) issue of a maximum of 5,883,817 shares with preferential rights for existing...
regulatorisk
2025-02-10 14:00
Qlife publishes information memorandum due to upcoming rights issue
The Board of Directors of Qlife Holding AB (“Qlife” or the “Company”) has, in connection with the Company's upcoming rights issue that was announced on 29 January 2025 (the “Rights Issue”), prepared...
regulatorisk
2025-02-06 09:00
QLIFE HOLDING AB, Interim Report Q4, October to December 2024
Financial summary – fourth quarter 2024 Revenue in the period amounted to kSEK 50 (30).  EBITDA for the period amounted to kSEK –7,721 (-86,903), and net loss kSEK – 7,106 (-111,545)....
regulatorisk
2025-01-31 20:34
Qlife comments on the CEO of the company getting a sanction from Finansinspektionen
The sanction relates to an incident in February 2023 when Thomas Warthoe forwarded an email with details related to a rights issue. The e-mail was forwarded to Peter Warthoe, CSO of the company and...
regulatorisk
2025-01-29 07:59
Qlife carries out a rights issue of approximately SEK 11.8 million and enters into an agreement for a credit facility of SEK 5.6 million
Today, the Board of Directors in Qlife Holding AB (“Qlife” or the “Company”) has, with the authorisation granted from the annual general meeting held on 26 June 2024, resolved to carry out an issue...
regulatorisk
2025-01-28 09:00
Qlife has signed a letter of intent with a top-20 global Pharma company to explore a potential commercial collaboration
Qlife is actively pursuing a partnership strategy and, with recent advancements in the Egoo Health product lines, expects to establish one or more partnerships during 2025. These collaborations will...
regulatorisk
2025-01-16 09:00
Qlife announces introduction of a CE-approved joint developed Egoo Health platform for immediate sales
Qlife and Hipro Biotechnology have joined forces to introduce a jointly developed, CE-IVD-marked platform to the market. This new solution combines the best of Hipro’s technology with Egoo Health’s...
icke regulatorisk
2025-01-14 09:00
Qlife provides sales and regulatory updates
The company has shifted its focus from research and development to becoming a sales-driven organization, emphasizing the distribution of its high-quality Egoo Health product platform in the rapidly...
icke regulatorisk
2025-01-07 09:00
Qlife provides update on operational progress in China
Since the summer, Qlife has been working diligently in close collaboration with its partner, Hipro Biotechnology, in China. The company is pleased to share the following updates: Excellent...
regulatorisk
2024-11-21 11:41
The exercise period for warrants of series TO 5 in Qlife Holding begins today, 21 November 2024
The exercise period for warrants of series TO 5 that were issued in conjunction with Qlife Holding AB's ("Qlife" or the "Company") rights issue of units in February 2024 (the "Rights Issue") begins...
regulatorisk
2024-11-19 13:23
Ny huvudansvarig revisor för Qlife Holding AB (publ)
Qlife har informerats om att Stefan Kylebäck kommer att efterträdas av Mattias Olofson som således kommer blir ny huvudansvarig revisor för Qlife. Bytet sker omgående. För ytterligare...
regulatorisk
2024-11-11 09:29
Qlife announces outcome in directed issues
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN, HONG KONG, SOUTH KOREA...
regulatorisk
2024-11-08 10:39
Kommuniké från extra bolagsstämma tillika andra kontrollstämma i Qlife Holding AB den 8 november 2024
Beslut om huruvida bolaget ska träda i likvidation eller driva verksamheten vidare Det konstaterades att den andra kontrollbalansräkningen utvisar att bolagets eget kapital är helt återställt. Med...
regulatorisk
2024-11-07 08:30
QLIFE HOLDING AB, Interim Report Q3, July to September 2024
Financial summary – third quarter 2024 Revenue in the period amounted to kSEK 0 (45). EBITDA for the period amounted to kSEK –27,151 (-6,660), and net loss kSEK – 28,087 (-8,926). The total...
regulatorisk
2024-10-07 20:06
Kallelse till extra bolagsstämma i Qlife Holding AB tillika andra kontrollstämma
Rätt att delta och anmälan Den som önskar delta i stämman ska: dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende förhållanden på avstämningsdagen som...
regulatorisk
2024-10-07 19:59
Qlife withdraws proposal to change company name
On 29 August 2024, Qlife announced its intention to change the Company’s name to Egoo Health AB as part of a broader rebranding initiative. However, the Swedish Companies Registration Office has...
icke regulatorisk
2024-10-02 08:55
Qlife starts sales of its PHE rare disease test, addressing an unmet need in the at-home testing market worth SEK 2.5 billion
An at-home PHE test will significantly improve the quality of life for people with Phenylketonuria. Qlife's regulatory strategy involves releasing the product as a CE-RUO test, backed by sufficient...
regulatorisk
2024-10-01 09:00
Qlife starts sales of its PHE rare disease test, addressing an unmet need in the at-home testing market worth SEK 2.5 billion
An at-home PHE test will significantly improve the quality of life for people with Phenylketonuria. Qlife's regulatory strategy involves releasing the product as a CE-RUO test, backed by sufficient...
regulatorisk
2024-09-10 09:00
Qlife is pleased to announce that Peter Warthoe will return to the management group as Chief Scientific Officer
Peter Warthoe is one of the co-founders of Qlife but decided a few years ago to step out of the management role to focus more on his scientific projects. Given the company’s new lean structure and...
regulatorisk
2024-09-06 13:03
Qlife Holding AB (publ) is pleased to announce that it publishes a second balance sheet for liquidation purposes showing that the Company's total equity exceeds the registered share capital
On 21 March 2024, the Company presented a balance sheet for liquidation purposes, showing that the equity was less than half of the registered share capital. On 28 March 2024, Qlife announced that...
icke regulatorisk
2024-09-04 09:00
Production of Egoo consumables now established in China to support on-going clinical trials and future sales
The Company reports that, in collaboration with its partner Hipro, progress has been made on the four key objectives set for their partnership. The integration and validation of Hipro biochemistry...
icke regulatorisk
2024-08-29 22:44
Qlife provides strategic business update and plans rebranding as 'Egoo Health' – a new era begins
As outlined in the press release dated 29 August 2024, Qlife has successfully executed directed issues of shares and warrants pursuant to the authority granted by the annual general meeting 2024....
regulatorisk
2024-08-29 22:33
Qlife acquires the assets of Qlife ApS, carries out directed issues of a total of approx. MSEK 6.90 and proposal of directed issues of approx. MSEK 5.05
Qlife Holding AB (publ) (“Qlife” or the “Company”) announces the acquisition of the assets of the Company's subsidiary Qlife ApS in bankruptcy, including goodwill and...
regulatorisk
2024-08-29 08:00
QLIFE HOLDING AB, Interim Report Q2, April to June 2024
Financial summary – second quarter 2024 Revenue in the period amounted to kSEK 39 (46). EBITDA for the period amounted to kSEK –8,002 (-16,287), and net loss kSEK –12,979 (-22,703). The total...
regulatorisk
2024-08-01 16:00
Qlife Holding AB (publ) meddelar omräkning av teckningsoptioner
Årsstämman i Qlife beslutade den 26 juni 2024 om sammanläggning av aktier 1:2000, innebärande att 2000 befintliga aktier läggs samman till 1 aktie. Styrelsen i Qlife fastställde avstämningsdagen för...
regulatorisk
2024-07-19 09:10
Qlife Holding AB’s subsidiary Qlife ApS terminates corporate restructuring and files for bankruptcy. Qlife Holding AB investigates a capital raise and to submit an offer to repurchase the assets.
Today, the reconstructor, has concluded that there is no viable path to secure financing for Qlife’s subsidiary, Qlife ApS. Consequently, the board of directors has decided to declare...
regulatorisk
2024-07-17 17:44
Avstämningsdag för sammanläggning av aktier i Qlife Holding AB
Sammanläggning av aktier Årsstämman beslutade den 26 juni 2024 om sammanläggning av aktier varigenom tvåtusen (2 000) befintliga aktier läggs samman till en (1) aktie. För att möjliggöra...
icke regulatorisk
2024-07-02 09:00
Qlife participates research trial for people living with PKU and gets positive data
For a couple of weeks during June Qlife was invited to participate Emory’s Metabolic Camp and run a research trial with the aim of making a comparison study of blood data on Egoo compared to data...
regulatorisk
2024-06-26 11:34
Kommuniké från årsstämma 2024 i Qlife Holding AB
Qlife Holding AB höll den 26 juni 2024 årsstämma varvid i huvudsak följande beslut fattades. Fastställande av räkenskaper samt resultatdisposition Årsstämman beslutade att fastställa resultat- och...
regulatorisk
2024-06-24 12:44
Qlife Holding AB loses arbitration proceedings against Aidian
On 13 March 2023, Qlife Holding AB (“Qlife” or the “Company”) announced that Aidian Oy had initiated arbitration proceedings against Qlife’s wholly owned subsidiary Qlife ApS regarding payment of...
regulatorisk
2024-06-10 15:08
Qlife Holding AB publishes information by reason of ongoing negotiations with Atlas Special Opportunities, LLC, regarding a financing solution
Qlife Holding AB (“Qlife” or the “Company”) and Atlas Special Opportunities, LLC (“Atlas”), have entered into a non-binding term sheet on 13 May 2024. According to the term sheet, Atlas will fund the...
regulatorisk
2024-06-07 12:41
Qlife Holding AB: The exercise period for warrants series TO 4 in Qlife Holding begins today
Terms for warrants series TO 4 in brief: The exercise price is SEK 0.02 per share. The exercise period runs from 7 – 21 June 2024. Each warrant entitles the holder to subscribe for one (1) share...
regulatorisk
2024-06-05 20:04
Qlife Holding AB publicerar årsredovisning för 2023
Årsredovisningen kan laddas ner från hemsidan eller beställas från Qlife, info@egoo.health. För ytterligare information vänligen kontakta: Thomas Warthoe, VD Qlife Holding Epost: tw@egoo.health...
regulatorisk
2024-06-03 09:00
Qlife starts clinical trial in China with first biomarker on Egoo Health
Since last year, Qlife has worked diligently towards transferring the Egoo Health platform to Hipro in China to setup pilot production of consumables, validate performance with Hipro reagents, and...
regulatorisk
2024-05-28 08:30
QLIFE HOLDING AB, Interim Report Q1, January to March 2024
Financial summary – first quarter 2024 Revenue in the period amounted to kSEK 0 (123). No revenue of Egoo.Health devices and capsules for the device. EBITDA for the period amounted to kSEK –11,...
regulatorisk
2024-05-26 22:00
Kallelse till årsstämma 2024 i Qlife Holding AB
Rätt att delta och anmälan Den som önskar delta i stämman ska: dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende förhållanden på avstämningsdagen som...
regulatorisk
2024-05-08 07:46
Qlife Holding AB enters into an addendum with the holders of the company’s convertible debentures and all outstanding convertible debentures are converted into shares
On 3 August 2024, the board of directors of the Company resolved on a directed issue of convertible debentures, with a total owed amount before interest of SEK 7,745,058 (including the set-up fee)....
regulatorisk
2024-04-23 09:55
Bulletin from the extraordinary general meeting, and the first meeting for liquidation purposes, in Qlife Holding AB on 23 April 2024
Resolution on whether the company shall enter into liquidation or continue its operations The extraordinary general meeting resolved in accordance with the primary proposal from the board of...
regulatorisk
2024-04-05 09:57
CORRECTION Qlife informs that it has put its Danish operational company into reconstruction mode as a temporary measure
“Qlife is following our operational plans, but since we have a called for an extraordinary general meeting later this month to resolve on the company’s balance sheet, we have chosen at the same time...
regulatorisk
2024-04-04 16:14
Qlife informs that it has put its Danish operational company into reconstruction mode as a temporary measure
“Qlife is following our operational plans, but since we have a called for an extraordinary general meeting later this month to resolve on the company’s balance sheet, we have chosen at the same time...
regulatorisk
2024-03-28 11:17
Qlife announces the last day for trading in BTU and the first day for trading in warrants series TO 4 and TO 5
The rights issue of units that was announced on 12 December 2023 (the “Rights Issue”) in Qlife Holding AB (“Qlife” or the “Company”) has been registered with the Swedish Companies Registration Office...
icke regulatorisk
2024-03-27 11:38
UPDATE: Qlife is emphasizing its strategy to finalize regulatory and Go-To-Market in China, register in Asian countries through partners, and then file for approval in the UK and EU
It has been mentioned in the media that Qlife is no longer focused on the EU and other markets. However, as communicated previously, Qlife is focused on finalizing regulatory work in China and roll-...
regulatorisk
2024-03-25 08:00
Qlife signs letter of intent with South Korean company Precision Biosensor as part of B2B strategy to enter major markets with Egoo Health, through hospital@home partnerships
Qlife is pleased to announce that it has signed a Letter of Intent (LOI) with leading South Korean company Precision Biosensor, to introduce Egoo Health to the South Korean market. Qlife anticipates...
regulatorisk
2024-03-21 18:25
Notice of extraordinary general meeting, and the first meeting for liquidation purposes, in Qlife Holding AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders of Qlife Holding AB...
icke regulatorisk
2024-03-21 17:33
UPDATE: Qlife is emphasizing that the call today for an extraordinary general meeting (EGM) is a necessity according to Swedish law, but that the company otherwise is following its plans.
Qlife has today called for an EGM because it is obliged to do so when the company has written down half of its equity as previously communicated in connection with the company’s year-end report for...
regulatorisk
2024-03-21 15:48
Qlife has prepared a balance sheet for liquidation purposes and the board of directors will convene an extraordinary general meeting (for liquidation purposes)
As communicated in the Company’s year-end report for the financial year 2023, the board of directors of Qlife has, in accordance with Chapter 25, Section 13 of the Swedish Companies Act, prepared a...
regulatorisk
2024-02-29 20:14
Qlife publishes outcome in rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
icke regulatorisk
2024-02-23 17:43
The subscription period in Qlife’s rights issue ends on Monday, February 26, 2024
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
icke regulatorisk
2024-02-23 13:48
Qlife’s core patent granted in Europe
The key feature of the innovation is the ability to perform analysis in a microenvironment with fixed alignment, so no variability is seen between analysis and readout. “This core patent protects...
icke regulatorisk
2024-02-16 09:00
Qlife reports first milestone achieved and on track with Chinese collaboration
The collaboration consists of four major parts: Integration of reagents Regulatory approval in China Distribution and sales in China Production of Egoo in China Integration of reagents The...
icke regulatorisk
2024-02-12 17:40
The subscription period in Qlife’s rights issue begins today
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
regulatorisk
2024-02-09 16:46
Qlife publishes prospectus due to upcoming rights issue of units
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
regulatorisk
2024-02-09 11:51
CORRECTION Qlife Q4 2023
Financial summary – fourth quarter 2023 Revenue in the period amounted to kSEK 30 (1,097). Revenue includes sales of Egoo.Health devices and capsules for the device. Revenue in Q4 is...
regulatorisk
2024-02-09 10:32
QLIFE HOLDING AB, Interim Report Q4, January to December 2023
Financial summary – fourth quarter 2023 Revenue in the period amounted to kSEK 30 (1,097). Revenue includes sales of Egoo.Health devices and capsules for the device. Revenue in Q4 is solely from...
regulatorisk
2024-02-04 21:53
Qlife postpones the publication of the year-end report for the financial year 2023 until 8 February 2024
The postponement is due to administrative reasons. This information was submitted for publication, through the agency of the contact person set out above, on 2024-02-04 21:53 CET.
regulatorisk
2024-01-16 11:21
Bulletin from the extraordinary general meeting in Qlife Holding AB on 16 January 2024
Resolution on (A) amendment of the Articles of Association; and (B) reduction of the share capital without redemption of shares The extraordinary general meeting resolved in accordance with the...
regulatorisk
2023-12-12 23:15
Notice of extraordinary general meeting in Qlife Holding AB
Right to participate and notification Shareholders wishing to participate in the meeting must: partly be listed in the company’s share register kept by Euroclear Sweden AB as of Monday 8 January...
regulatorisk
2023-12-12 22:10
Qlife carries out a rights issue of units of approximately SEK 49.5 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
icke regulatorisk
2023-12-07 09:00
Qlife collaboration agreement with Hipro biotechnology - potential value of 500 MSEK
Qlife has on Monday 4th of December entered into a final collaboration agreement with Hipro Biotechnology. The parties will from now on work diligently towards achieving market clearance for Egoo...
icke regulatorisk
2023-12-04 10:00
Qlife signs collaboration agreement with Hipro Biotechnology
The agreement in brief The agreement consists of four major parts: Integration of reagents Regulatory approval from the China Food and Drug Administration for Egoo Health Distribution and sales...
regulatorisk
2023-12-01 08:00
Management changes in Qlife Holding AB
Peter Thorsen is a Certified Public Accountant (CPA) with an impressive background in finance, having previously served in key roles at prominent organizations such as EY, DSV A/S, Domea, Widex A/S,...
regulatorisk
2023-11-13 10:00
Qlife Holding AB, Interim report Q3, January to September 2023
Financial summary – third quarter 2023 Revenue in the period amounted to kSEK 45 (1,967). Revenue includes sales of Egoo. Health devices and capsules for the device. Revenue in Q3 is solely...
regulatorisk
2023-10-03 12:12
Qlife Holding announces the outcome of the exercise of warrants series TO 3
In total, Qlife issued 622,348,940 units in the Rights Issue, each consisting of one (1) share and one (1) warrant series TO 3. One (1) warrant entitled the right to subscribe for one (1) new share...
regulatorisk
2023-09-14 09:57
Qlife signs letter of intent with major industry partner as part of the B2B strategy to enter major markets with Egoo Health, through hospital-at-home partnerships.
The technology and overall strategy Qlife has invested more than SEK 300 million in the development of Egoo Health, a unique biomarker self-testing system for measuring and monitoring blood data...
regulatorisk
2023-09-11 08:45
The exercise period for warrants series TO 3 in Qlife Holding begins today
Terms for warrants series TO 3 in brief:   The exercise price is SEK 0.11 per share. The exercise period runs from 11 – 29 September 2023. Each warrant entitles the holder to...
regulatorisk
2023-08-17 08:45
QLIFE HOLDING AB, Interim Report Q2, January to June 2023
Financial summary – second quarter 2023 In Q2 2023 QLife has completed restructuring of its operation by reducing the number of employees and terminating a long term lease for...
regulatorisk
2023-08-03 14:24
Qlife carries out a SEK 4,6m directed issue of convertibles
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
icke regulatorisk
2023-07-27 23:52
Launch of Egoo Innovate attracts attention at AACC/Clinical Lab
At AACC/Clinical Lab Expo, the open system Egoo Innovate was launched and Qlife demonstrated how Egoo Innovate can be a game-changer in promoting faster and targeted implementation of critical...
icke regulatorisk
2023-06-27 10:00
Launch of Egoo Innovate at AACC - to promote faster and targeted implementation of critical biomarker assays into at-home testing
The open system provides the opportunity of innovating and implementing proprietary biomarker assay projects on to the at-home diagnostic system. Now, researchers can join the quest to broaden access...
regulatorisk
2023-06-26 16:38
Qlife Holding announces the outcome of the exercise of warrants series TO 2
In total, Qlife issued 2,884,980 units in the Rights Issue, each consisting of one (1) share and one (1) warrant series TO 2. One (1) warrant entitled the right to subscribe for 1.08 new shares in...
icke regulatorisk
2023-06-26 15:42
Qlife to reduce costs further by terminating lease
Since the start of 2023, Qlife has continuously scaled down on costs, workforce and operates mainly by outsourcing. The termination of the lease is part of Qlife’s new operation model to implement...
icke regulatorisk
2023-06-26 10:00
Qlife to make its Egoo technology available as an open system to facilitate development and accelerate revenue streams
“Since the IPO in March 2020 Qlife has achieved a lot of encouraging goals”, says CEO Thomas Warthoe. “We have continuously listened to the market to adjust our offers and have now concluded that we...
regulatorisk
2023-06-07 08:30
The exercise period for warrants series TO 2 in Qlife Holding begins today
Terms for warrants series TO 2 in brief: The exercise price has been set to SEK 0.21 per share. The exercise price has been defined as seventy (70) per cent of the volume-weighted average price...
regulatorisk
2023-05-30 22:03
Qlife announces the last day for trading in BTU and the first day for trading in warrants series TO 3
The rights issue of units that was announced on 16 February 2023 (the “Rights Issue”) in Qlife Holding AB (“Qlife” or the “Company”) has been registered with the Swedish Companies Registration Office...
regulatorisk
2023-05-26 09:00
QLIFE HOLDING AB, Interim Report Q1, January to March 2023
Financial summary – first quarter 2023 Revenue in the period amounted to kSEK 123 (10,905). Revenue includes sales of Egoo.Health devices and capsules for the device. COVID test...
regulatorisk
2023-05-05 10:27
Bulletin from the annual general meeting in Qlife Holding AB 4 May 2023
On 4 May 2023, the annual general meeting was held in Qlife Holding AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority. Resolution on...
regulatorisk
2023-05-03 19:17
Qlife carries out directed issue of units to guarantors in connection with rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
regulatorisk
2023-04-27 16:39
Qlife publishes outcome in rights issue and information on warrants series TO 2
Subscription and allotment The subscription summary shows that 122,853,750 units, corresponding to approximately 21.3 percent of the Rights Issue, were subscribed for by exercise of unit rights. In...
regulatorisk
2023-04-19 18:04
Qlife publishes supplementary prospectus
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
regulatorisk
2023-04-13 09:50
Qlife fully secures ongoing rights issue with top guarantee commitments
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
regulatorisk
2023-04-06 12:38
Qlife publishes prospectus due to upcoming rights issue of units
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
regulatorisk
2023-04-05 11:24
QLIFE PUBLISHES ANNUAL REPORT 2022
The full report is available in English at the following url.: https://qlifeholding.com/en/investors/finansiella-rapporter Qlife has changed to English as the sole language for market...
regulatorisk
2023-04-03 16:00
Kallelse till årsstämma i Qlife Holding AB
Rätt att delta och anmälan Aktieägare som önskar delta i årsstämman ska: dels vara införd i den av Euroclear Sweden AB förda aktieboken tisdagen den 25...
regulatorisk
2023-04-03 14:22
The Nomination Committee’s proposals for new board members in Qlife
Qlife’s Nomination Committee proposes that the Annual General Meeting elects Lars Bangsgaard as new Chairman of the Board, Lars Wegner as new Board member and re-election of Mette-Marie Harild,...
regulatorisk
2023-03-24 14:45
Kommuniké från extra bolagsstämma i Qlife Holding AB den 24 mars 2023
Beslut om ändring av bolagsordningen Den extra bolagsstämman beslutade i enlighet med styrelsens förslag att ändra bolagsordningen så att gränserna för...
icke regulatorisk
2023-03-13 22:16
Qlife announces that Aidian has initiated arbitration proceedings against Qlife
In 2020, Qlife entered into a cooperation with the Finnish company Aidian Oy. Several agreements between the parties were concluded in 2020 and 2021, according to which Qlife undertook to purchase...
regulatorisk
2023-02-16 23:39
Kallelse till extra bolagsstämma i Qlife Holding AB
Rätt att delta och anmälan Aktieägare som önskar delta i stämman ska: dels vara införd i den av Euroclear Sweden AB förda aktieboken torsdagen den 16 mars 2023; dels anmäla sig till bolaget...
regulatorisk
2023-02-16 23:37
Qlife carries out a rights issue of units of approximately SEK 57.7 million
Summary of the Rights Issue The Rights Issue is proposed to be carried out on the following main terms: The Rights Issue comprises a maximum of 576,813,400 units, corresponding to a maximum of...
regulatorisk
2023-02-16 11:57
QLIFE HOLDING AB, Interim Report Q4, January to December 2022
Financial summary – fourth quarter 2022 Revenue in the period amounted to kSEK 1,097 (12,084). Revenue includes sales of Egoo.Health devices and capsules for the device. COVID test...
regulatorisk
2023-02-16 10:00
QLIFE HOLDING AB, Interim Report Q4, January to December 2022
Financial summary – fourth quarter 2022 Revenue in the period amounted to kSEK 1,097 (12,084). Revenue includes sales of Egoo.Health devices and capsules for the device. COVID test...
icke regulatorisk
2023-02-15 12:00
Qlife’s web shop for the Egoo Health with CRP Capsule is now open
“With this launch, Qlife really can start delivering on our vision of bringing lifestyle biomarker testing with quantitative precise data to a wider health-conscious audience and for home use”, says...
icke regulatorisk
2023-01-23 10:00
Qlife reaches important milestone: launches Egoo Health and CRP test
With the launch of our CRP capsule, Qlife will start delivering on our vision of bringing lifestyle biomarker testing with quantitative precise data to a wider health conscious audience and for home...
icke regulatorisk
2023-01-11 09:00
Qlife completes freeze-drying project necessary for home-use
Qlife has been able to develop a small, freeze-dried bead that consist of the CRP reagents used in the Egoo CRP Capsule. Instantly frozen reagents which then are freeze-dried into spherical beads are...
regulatorisk
2022-11-29 16:54
Correction: Qlife Holding AB, Interim report Q3 2022
Financial summary – third quarter 2022   Revenue in the period amounted to kSEK 1,967 (5,871). Revenue includes sales ofEgoo.Health devices and capsules for the device. Continued...
regulatorisk
2022-11-25 10:00
Qlife Holding AB, Interim report Q3 2022
Financial summary – third quarter 2022   Revenue in the period amounted to kSEK 1,967 (5,871). Revenue includes sales ofEgoo.Health devices and capsules for the device. Continued...
icke regulatorisk
2022-11-22 15:09
Kasper Rousøe, CFO of Qlife presents at Redeye Life Science Day 2022.
On November 24th at 14:20 Qlife's CFO, Kasper Boel Rousøe will presentthe latest developments in the company at Redeye. We will do an in-depth interview, called InFocus. The interview will...
regulatorisk
2022-11-02 18:00
Qlife announces the last day for trading in BTU and the first day for trading in warrants series TO 2022
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
regulatorisk
2022-10-20 19:00
Qlife announces outcome in rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
icke regulatorisk
2022-10-12 08:00
Qlife takes Egoo Health to Biohacker Summit 2022 – to engage with potential consumers and gain industry insights
This is the largest biohacker event in the world and gathers people, companies, and organizations across the medical, health, and wellbeing sector, providing an optimal platform for networking,...
icke regulatorisk
2022-09-30 11:46
Qlife reduces operational costs - workforce reductions and restructuring
During the past year, Qlife has been transitioning and transforming to a post-covid reality. The current cost reductions are related to a significantly reduced demand for covid-tests and primarily...
icke regulatorisk
2022-09-20 09:00
Qlife to participate in investor presentations in September 2022
September 26 at Stora Aktiedagen in Lund Venue: Elite Hotel Ideon Time: 08.30-09.00 The presentation will be held in English and the event is open to the public, as well as live-streamed and...
icke regulatorisk
2022-08-18 08:30
Qlife updates vision and websites – reinforced emphasis on making Egoo Health available for home use
Qlife was founded based on the idea that Egoo Health could help people lead a better life by using the diagnostics self-testing platform Egoo Health. Today, the short-term focus is on completing...
icke regulatorisk
2022-04-04 12:35
Pressmeddelande inte längre på svenska
Från den 1 april 2022 publicerar Qlife inte längre pressmeddelanden på svenska. Alla nyheter finns här (https://qlifeholding.com/en/investors/news).
icke regulatorisk
2022-03-28 10:42
Qlife följer upp studie - avvikelser i testutförande förklarar felaktiga resultat
Som studieupplägg använde Hvidovre Hospitals best practice för covid-19-testning (RT-qPCR) som jämförelsemetod. Därmed avviker testutförande från den för Egoo.Healths avsedda användningen och...
icke regulatorisk
2022-02-17 10:12
Qlife följer upp dansk klinisk utvärdering av snabbtester för covid-19
"Vi är överraskade att resultatet från den danska utvärderingen skiljer sig från en annan vetenskaplig och publicerad studie omfattande mer än 1000 prover som bland annat genomförts tillsammans...
regulatorisk
2022-02-17 09:30
QLIFE HOLDING AB BOKSLUTSKOMMUNIKÈ Q4, 2021
FJÄRDE KVARTALET 1 OKTOBER - 31 DECEMBER 2021 Periodens intäkter uppgick till 12 084 (9 122) KSEK. Försäljning avser Egoo.Health enheter och COVID-19 test kapslar. EBITDA för perioden uppgick...
regulatorisk
2021-12-20 16:00
Qlife får finansiering på 3,45 MUSD från FIND för att utveckla ett respiratoriskt test i den globala kampen mot COVID-19 och influensa
Qlife har tecknat ett avtal med FIND, the global alliance for diagnostics, om en finansiering på 3,45 MUSD för ett 12-månaders projekt med målet att utveckla ett nytt två-i-ett-test för upptäckt av...
regulatorisk
2021-11-29 11:34
Qlife utser Kasper Damgaard Rousøe till ny CFO
Kasper Rousøe har mer än 20 års erfarenhet från ledande roller inom det finansiella området, senast från Phase One A/S. Han har tidigare varit CFO och finansdirektör i Bauer Media Group, Mono...
regulatorisk
2021-11-08 08:30
QLIFE HOLDING AB KVARTALSRAPPORT Q3, 2021
TREDJE KVRATALET 1 JULI - 30 SEPTEMBER 2021 Periodens intäkter uppgick till 5 871 (5 062) KSEK och avser försäljning av COVID-19 tester från servicecenter, samt Egoo.Health enheter och ...
icke regulatorisk
2021-11-03 16:27
Qlife har fått den första vetenskapliga studien på sitt COVID-19-test med det mobila Egoo Health-systemet publicerad i Natures Scientific Reports
Idag får de flesta sin diagnos genom så kallad kvantitativ polymeraskedjereaktion (qRT-PCR) som utförs i specialiserade laboratorier. Det innebär att det ofta tar mer än 24...
icke regulatorisk
2021-10-26 13:50
Valberedning utsedd inför Qlife Holding årsstämma 2022
I enlighet med beslutet vid Qlife Holding årsstämma 2021 har bolagets styrelseordförande sammankallat en valberedning för att förbereda förslag inför bolagets årsstämma 2022. Valberedningen består av...
icke regulatorisk
2021-10-14 15:17
Qlife genomför investerarpresentationer i december 2021
Onsdagen den 1 december på Stora Aktiedagen i Stockholm Kl 12.00-12.30 Torsdagen den 2 december på Västra Hamnen i Malmö Kl. TBD Investerare, analytiker och media behöver anmäla sig till...
regulatorisk
2021-09-21 16:30
Niklas Marschall lämnar styrelsen i Qlife Holding AB
”Det har varit en fantastisk resa som jag är stolt över att ha varit med på. Min expertis är framförallt att bistå bolag i uppstartsfas, och det är Qlife verkligen inte längre, och därför är det rätt...
regulatorisk
2021-08-16 08:30
QLIFE HOLDING AB KVARTALSRAPPORT Q2, 2021
ANDRA KVRATALET 1 APRIL - 30 JUNI 2021 Periodens intäkter uppgick till 10 482 (6 181) KSEK och avser försäljning av COVID-19 tester från servicecenter, samt Egoo.Health enheter och kapslar....
icke regulatorisk
2021-07-15 12:12
Qlife har lämnat in en vetenskaplig studie av bolagets COVID-19-test för peer-review för publicering i en internationell tidskrift
De flesta får idag sin diagnos genom så kallad kvantitativ polymeraskedjereaktion (qRT-PCR) som utförs i specialiserade laboratorier. Det innebär att det ofta tar mer än 24 timmar från testtillfälle...
icke regulatorisk
2021-06-10 08:00
Qlife utökar testkapaciten för Covid-19 under EM i fotboll i Köpenhamn
I samband med EM i fotboll i Köpenhamn de närmaste veckorna utökar Qlife sin testkapacitet för Covid-19 för att ge fler tillgång till RT-PCR-testning med garanterad respons inom 8 timmar (svar samma...
icke regulatorisk
2021-06-09 12:30
Qlifes grundare delar upp ägandet i fyra ägarbolag
Uppdelningen innebär att Thomas Warthoes, Peter Warthoes och Lars Bangsgaards respektive bolag har förvärvat 1 201 200 aktier var av PKV Consult IVS, och Ebbe Finding är nu ensam ägare av...
regulatorisk
2021-06-02 08:00
Teckningsoptioner av serie TO 1 tecknades till cirka 97,4 procent och Qlife Holding tillförs cirka 38,1 MSEK
Utnyttjandeperioden för teckningsoptionerna av serie TO 1 ägde rum från och med den 3 maj 2021 till och med den 31 maj 2021. Teckningskursen per aktie för utnyttjande av teckningsoptionerna av serie...
regulatorisk
2021-05-20 08:00
Styrelseledamöter i Qlife tecknar optioner
Vid årsstämman den 5 maj 2021 beslutades om ett incitamentsprogramprogram riktat till tre nya styrelseledamöter i bolaget. Optionsvillkoren baseras på en marknadsmässig värdering enligt...
icke regulatorisk
2021-05-18 08:00
Qlife’s styrelse och ledning nyttjar innehavda teckningsoptioner av serie TO1 för 2,4 MSEK
Innehavare av teckningsoptioner äger rätt att för varje två (2) ägda teckningsoption av serie TO1 teckna en (1) ny aktie i Qlife till ett pris om 17,50 SEK per aktie. Antalet teckningsoptioner av...
regulatorisk
2021-05-05 12:46
Kommuniké från årsstämma i Qlife Holding AB den 5 maj 2021
Beslut om fastställande av räkenskaper samt resultatdisposition Årsstämman beslutade att fastställa resultat- och balansräkning samt koncernresultat- och koncernbalansräkning. Årsstämman beslutade...
regulatorisk
2021-05-05 08:00
QLIFE HOLDING AB KVARTALSRAPPORT 2021, Q1
FÖRSTA KVARTALET 1 JANUARI - 31 MARS 2021 Periodens intäkter uppgick till 11 176 (385) KSEK och avser försäljning av COVID-19 tester från servicecenter och Egoo.Health enheter och kapslar för...
regulatorisk
2021-05-03 08:00
Nyttjandeperiod av teckningsoptioner i Qlife Holding AB serie TO 1 inleds i dag den 3 maj 2021
Nyttjandeperioden pågår från och med den 3 maj 2021 fram till och med den 31 maj 2021. Två (2) teckningsoptioner berättigar till teckning av en (1) ny aktie i Bolaget...
regulatorisk
2021-04-29 19:02
Qlife Holding AB genomför en riktad nyemission om cirka 90 MSEK.
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SINGAPORE, SYDAFRIKA...
icke regulatorisk
2021-04-23 11:30
Qlife bjuder in till rapportpresentation av Q1 2021, den 5 maj 2021
Qlife bjuder in investerare, analytiker och media till en presentation av kvartalsrapporten där CEO Thomas Warthoe ger sina kommentarer på rapporten. Rapporten släpps klockan 08:00 och kommer att...
regulatorisk
2021-04-22 14:24
Qlife lämnar utvecklingsprogram på Herlev Hospital
Qlife har varit en del av ett utvecklingsprogram vid onkologiavdelningen på Herlev Hospital sedan 2018, avsett att validera monitorering i hemmet av njurcancerpatienter. Projektet har försenats flera...
regulatorisk
2021-04-21 13:07
QLIFE tecknar exklusivt europeiskt distributionsavtal med Aidian
Avtalet omfattar en rad europeiska länder, inklusive Sverige, Norge, Finland, Tyskland, Nederländerna, Belgien, Luxemburg, Österrike, Schweiz, Polen, Tjeckien, Ungern, Slovakien, Rumänien, Slovenien...
regulatorisk
2021-04-12 08:00
Qlife publicerar årsredovisning för 2020
Årsredovisningen kan laddas ned från hemsidan eller beställas från bolaget, info@egoo.health.Informationen är sådan som Qlife Holding AB är skyldigt att offentliggöra enligt lag (2007:528) om...
regulatorisk
2021-03-31 20:15
Rättelse: Kallelse till årsstämma i Qlife Holding AB
Aktieägarna i Qlife Holding AB, org. nr 559224-8040 (”Qlife”), kallas till årsstämma onsdagen den 5 maj 2021. Mot bakgrund av den pågående covid-19-pandemin och i syfte att minska risken för...
regulatorisk
2021-03-31 08:15
Kallelse till årsstämma i Qlife Holding AB
Mot bakgrund av den pågående covid-19-pandemin och i syfte att minska risken för smittspridning har styrelsen beslutat att årsstämman ska hållas enbart genom förhandsröstning (poströstning) med stöd...
regulatorisk
2021-03-31 08:00
Valberedningens förslag till nya styrelseledamöter i Qlife
Qlife’s valberedning föreslår att årsstämman väljer Mette-Marie Harild, Ulrik Harrysson och Mikael Persson till nya styrelseledamöter. Mette-Marie Harild, född 1958, har lång erfarenhet av att leda...
regulatorisk
2021-02-18 10:01
QLIFE HOLDING AB Bokslutskommuniké 2020, Q4
FJÄRDE KVARTALET 1 OKTOBER - 31 DECEMBER 2020 Periodens intäkter uppgick till 9 122 (0) KSEK och avser försäljning av COVID-19 testkapasitet till kunder främst inom sport genom samarbetspartnern...
icke regulatorisk
2021-01-29 08:00
Qlife erhåller order för COVID-19 test från danska Statens Serum Institut
”Det är mycket viktigt för Qlife att vi erhåller en betydande order från en mycket professionell kund direkt efter vår CE-märkning. Det visar på efterfrågan för testning med laboratoriekvalitet med...
icke regulatorisk
2021-01-25 08:00
Qlife beviljas sitt första patent för Egoo.Health-enheten
Danska patentverket har beviljat Qlife patentnummer DK180348 B1 för sin detekteringsenhet för biomarkörer. Enheten för biomarkörsdetektering består av ett integrerat optiskt mikroelektromekaniskt...
icke regulatorisk
2021-01-07 08:00
Qlife CE-märker COVID-19 test
Det aktuella CE-märkningen gäller för professionell användning av testplattformen Egoo.Health och för försäljning på den europeiska marknaden. Nästa steg är att placera COVID-19 testet på strategiska...
regulatorisk
2020-12-22 10:54
Qlife upptar lån om 15 MSEK för att stärka rörelsekapitalet inför kommande marknadslansering
Qlife förväntar CE-märkning för professionell användning av Bolagets COVID-19 test i Egoo.Health-systemet inom kort. Med CE-märkningen kan Qlife’s kostnadseffektiva, snabba och mobila PCR-test...
icke regulatorisk
2020-11-30 08:00
Qlife ökar decentraliserad testning av professionell fotboll i Danmark med Divisionsforeningen - Egoo. Health-plattformen placeras i tre klubbar
Sedan maj 2020 har Qlife hanterat alla tester för COVID-19 för professionell fotboll i Danmark. Testkapaciteten inkluderar veckovis testning av alla spelare och personal i ligaklubbar för att minska...
icke regulatorisk
2020-11-27 13:53
Qlife besvarar inte preliminärt avslag av Lægemiddelstyrelsen för COVID-19 test – fokuserar på att få CE-märking vid årsskiftet
Den 13 november fick Qlife beskedet från Lægemiddelstyrelsen att bolagets ansökan om tillfälligt godkännande i Danmark ”i hälsoskyddets intresse” för bolagets COVID-19 test får preliminärt...
icke regulatorisk
2020-11-24 08:46
Qlife receives order for COVID-19 tests to European Women’s Handball Championship 2020
”We will do our utmost to protect the participating players against the coronavirus”, says Frank Smith, Covid-19 Officer, European Handball Federation Euro 2020 “It requires testing with high...
regulatorisk
2020-11-19 11:30
Kommuniké från extra bolagsstämma i Qlife Holding AB
Beslut om (A) personaloptionsprogram; och (B) riktad emission av teckningsoptioner samt godkännande av överlåtelse av teckningsoptioner Stämman beslutade i enlighet med styrelsens förslag att...
regulatorisk
2020-11-18 11:46
QLIFE HOLDING AB KVARTALSRAPPORT Q3, 2020
TREDJE KVARTALET 1 JULI - 30 SEPTEMBER 2020 Periodens intäkter uppgick till 5 062 (714) KSEK och avser försäljning av COVID-19 testkapasitet till kunder främst inom sport, genom samarbetspartnern...
regulatorisk
2020-11-13 17:54
Qlife: ansökan om tillfälligt godkännande i Danmark ”i hälsoskyddets intresse” får preliminärt avslag av Lægemiddelstyrelsen
Parallellt med den pågående processen att förbereda och sammanställa dokumentationen för CE-godkännandet, har Qlife lämnat in en ansökan om att lansera produkten i Danmark, eftersom det innebär en...
icke regulatorisk
2020-11-03 08:51
Valberedning utsedd inför Qlife Holding's årsstämma 2021
Valberedningen består av följande personer, vilka tillsammans representerar cirka 39 procent av antalet aktier och röster i bolaget baserat på senast kända aktieägarinformation: Sören Skjärbäk,...
regulatorisk
2020-11-02 08:30
Kallelse till extra bolagsstämma i Qlife Holding AB
Information med anledning av coronaviruset Som en försiktighetsåtgärd för att minska risken för spridning av coronaviruset har styrelsen i Qlife Holding AB (”Qlife”) beslutat att begränsa planerade...
regulatorisk
2020-10-30 12:00
Qlifes CE-godkännande för COVID-19 test försenat 2-3 månader – ansökan inlämnad om tillfälligt godkännande i Danmark ”i hälsoskyddets intresse”
Qlife förväntade ett CE-godkännande för produkten under oktober, men bolaget förväntar nu godkännandet inom kommande två till tre månader. Parallellt har Qlife lämnat in en ansökan till danska...
icke regulatorisk
2020-08-21 13:55
Qlife to expand their COVID-19 testing to include all professional handball in Denmark
Due to the increasing of infectious rates over the past few weeks, it has been agreed that Qlife will be handling all testing for COVID-19 for professional handball in Denmark. Testing will start...
regulatorisk
2020-08-18 09:46
QLIFE HOLDING AB HALVÅRSRAPPORT Q2, 2020
ANDRA KVARTALET 1 APRIL - 30 JUNI 2020 Periodens intäkter uppgick till 6 181 (0) KSEK och avser i huvudsak försäljning till KMD avseende avtal med Danska Fotbolls Ligan för att testa spelare och...
icke regulatorisk
2020-07-30 15:15
Qlife extends contract with Divisionsforeningen
In cooperation with KMD, Qlife has extended the contract with Divisionsforeningen. The extended contract is the continuation of COVID-19 testing of players and personnel in the two best football...
icke regulatorisk
2020-07-17 15:55
Qlife continues to work with professional sports, now abroad and within cycling
Qlife's focus on professional sports is centered around COVID-19 testing, which the company offers in collaboration with IT partner KMD. COVID-19 testing contracts have been closed with various...
icke regulatorisk
2020-07-06 20:40
Nyhetsbrev - kommersiella aktiviteter och kommunikation
In April we closed a contract with the professional Danish football league for regular testing of all players and staff for COVID-19 and delivery of test results were initiated already in week 22....
regulatorisk
2020-06-22 15:59
Henrik Ljung tar rollen som Chief Financial Officer, CFO, i Qlife Holding AB.
“Henrik Ljung tillför Qlife bred erfarenhet från såväl finansiell rapportering, IR, affärskontroll, finansledning som bolagsstyrning, allt med fokus på snabbväxande bolag i tidig fas. Det är med stor...
icke regulatorisk
2020-06-19 19:54
Qlife tests badminton players for COVID-19, for this weekend's RSL Final 4 play
KMD and Qlife has entered an agreement with Badminton Denmark to COVID-19 test all players in the final game of the Danish badminton tournament for clubs, RSL Final 4. "The fact that we COVID-19...
icke regulatorisk
2020-06-04 11:24
MOVING CLOSER TO THE MARKET - PROFESSIONAL SPORTS, CULTURE AND ENTERTAINMENT
Geelmuyden Kiese and KMD announced earlier today that they have entered a partnership to provide smart and efficient Covid-19 test solutions for the professional sports, culture, and entertainment...
icke regulatorisk
2020-06-03 12:12
Qlife to develop SARS-CoV-2 total antibody test
The first phase of developing the antibody test will be outsourced to an existing partner and is expected to take approximately three months. Thereafter, the project will be transferred to in-house...
icke regulatorisk
2020-05-27 15:11
Status on Qlife’s COVID-19 tests
Qlife announced on 22 April that a research agreement had been made with Nordsjällands Hospital (NOH), for continued validation of the COVID-19 test. The validation at NOH was initiated immediately...
regulatorisk
2020-05-20 14:00
Kommuniké från årsstämma i Qlife Holding AB den 20 maj 2020
Beslut om fastställande av räkenskaper samt resultatdisposition Årsstämman beslutade att fastställa resultat- och balansräkning samt koncernresultat- och koncernbalansräkning. Årsstämman beslutade...
regulatorisk
2020-05-20 08:15
Qlife Holding AB delårsrapport januari – mars 2020
FINANSIELL SAMMANFATTNING FÖRSTA KVARTALET 2020 Periodens intäkter uppgick till 385 (0) KSEK och avser ett samarbetsprojekt med ett danskt sjukhus. EBITDA för perioden uppgick till -5 732 (-1 875...
regulatorisk
2020-05-13 18:36
Qlife has entered a first strategically important sales agreement for their COVID-19 test
The parties have agreed a testing plan for all players, judges and club staff for Covid-19 in the professional leagues (3F SuperLiga and NordicBet Liga). The parties have developed a test protocol...
icke regulatorisk
2020-04-22 20:58
Qlife enters agreement with Nordsjællands Hospital to start validation of COVID-19 test
Qlife announces that it has entered into a research agreement with Nordsjællands Hospital (NOH), to continue the validation of the Egoo Sars-CoV-2 virus test. The focus of the collaboration is to...
regulatorisk
2020-04-16 10:00
Kallelse till årsstämma i Qlife Holding AB
Information med anledning av coronaviruset Som en försiktighetsåtgärd för att minska risken för spridning av coronaviruset har styrelsen i Qlife Holding AB (”Qlife”) beslutat att begränsa planerade...
icke regulatorisk
2020-04-07 11:01
Qlife updates on process for COVID-19 test (Eng)
Due to increased requests for information on route to market for Qlife’s COVID-19 test the company is updating the following:  After having finalized the licensing agreement to COVID-19...
regulatorisk
2020-03-31 16:50
Qlife utvidgar Egoo.Health-plattformen till COVID-19-test genom licensavtal
Molekylär (DNA/RNA) virustestning var påtänkt att utvecklas för Egoo-plattformen i ett senare skede. Tack vare den senaste tidens positiva teknikintegration och den starkt ökade efterfrågan på...
icke regulatorisk
2020-03-13 16:30
Corona virus, COVID-19, has limited impact on Qlife Holding AB
Qlife went public on March 2 with a clear strategy for the next year, that strategy is still being followed and we do not see any large obstacles to it due to the Corona virus outbreak. The interest...
icke regulatorisk
2020-03-02 08:45
Handel med Qlife aktier inleds på Nasdaq First North Growth Market
Qlife Holding AB meddelar att handel i bolagets aktier (kortnamn QLIFE) och teckningsoptioner serie TO1 (QLIFE TO1) inleds idag på Nasdaq First North Growth Market i Stockholm. Qlife Holding AB (“...
icke regulatorisk
2020-02-28 12:27
Qlife är godkänt för listning på Nasdaq First North Growth Market med första handelsdag den 2 mars 2020
Aktiens kortnamn är QLIFE. Teckningsoptionerna av serie TO1 handlas under kortnamn QLIFE TO1. Qlife har anlitad G&W Fondkommission som certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@...
icke regulatorisk
2020-02-12 08:00
Qlife Holding AB:s listningsemission tecknades till cirka 280 procent
Qlife har genomfört en emission i Bolaget genom att inför den planerade listningen på Nasdaq First North Growth Market erbjuda allmänheten och institutionella investerare i Sverige och utomlands att...
icke regulatorisk
2020-01-29 12:30
Qlife tillkännager CE-märkning för professionell användning för sin första biomarkörkapsel på plattformen Egoo Home System.
Egoo Home System är en integrerad plattform som består av ett litet mätinstrument med tillhörande engångskapslar och mjukvara, där varje kapsel innehåller ett test för en specifik biomarkör. Den...
regulatorisk
2020-01-17 11:21
Medicinteknikbolaget Qlife Holding AB offentliggör prospekt avseende nyemission av units inför listningsansökan på Nasdaq First North Growth Market
Qlife är ett svenskt moderbolag till det helägda danska medicintekniska dotterbolaget Qlife ApS. Qlife ApS utvecklar en innovativ medicinteknisk produkt med det långsiktiga målet att ge människor...
icke regulatorisk
2019-11-28 10:38
Ny presentation från Stora Aktiedagen Stockholm den 25 Nov
VD Thomas Warthoe kommer att presentera Qlife på Stora Aktiedagen i Stockholm den 25/11. Vill ni läsa mer om dagarnas hela program och anmälan, se bifogad anmälan.  
icke regulatorisk
2019-11-06 10:20
Presentation av Qlife på Stora Aktiedagen
VD Thomas Warthoe kommer att presentera Qlife på Stora Aktiedagen i Göteborg den 4/11 och Stockholm den 25/11. Vill ni läsa mer om dagarnas hela program och anmälan, se bifogad anmälan.
icke regulatorisk
2019-11-06 09:12
Top Danish politicians were excited when testing their own biomarkers with Egoo
The home diagnostic device from Danish start-up Qlife can make the lives of patients with chronic diseases easier. This is the way forward towards a more human centered public health sector, says one...
icke regulatorisk
2019-10-31 14:15
Qlife præsenteres af den danske sundhedsminister og erhvervsminister
Qlife præsenteres af den danske sundhedsminister og erhvervsminister under lancering af nyt offentlig program som fremmer partnerskaber for innovationsfremmende sundhedsudbud for medicinsk udstyr...
icke regulatorisk
2019-10-17 12:38
Nyhetsbrev
I bifogade nyhetsbrev (enbart på engelska) får du uppdatering om vår verksamhet och våra förberedelser inför nästa steg.
icke regulatorisk
2019-10-03 08:31
Qlife medverkar på Intrum Stockholm Open den 18/10 2019!
Totalt sex intressanta bolag presenterar sin verksamhet. Se filmen från presentationen
icke regulatorisk
2019-10-03 08:31
Qlife talar på Healthcare IoT konferensen den 24/10 – hantering av patientdata en viktig framtida fråga!
Det danska sjukvårdssystemet producerar stora mängder data varje dag. I framtiden kommer nya datakällor såsom data från patienter och inte minst personliga hälsoinstrument och appar att få mängden...
icke regulatorisk
2019-10-03 08:30
Artikel Börsen den 6 augusti 2019. Alla kan snart testa sitt blod hemma!
Biologiska markörer i vårt blod kan visa mycket om vår hälsa, utvecklingen av en sjukdom eller eller hur hårt vi har drivit på kroppen under ett träningspass. Men det har hittills krävt tillgång till...

Qlife

Qlife Holding AB 
Nellickevägen 22
SE-412 63 Göteborg
info@egoo.health
Senast publicerad: 2025-02-10

Links

  • Om oss
  • Investerare
  • Egoo.health

Qlife grundades för att utmana utvecklingen inom dagens sjukvård. Vi arbetar för att ändra perspektivet och vända dagens syn på hälso- och sjukvård till morgondagens fokus på att ge patienten makt över sin hälsa. Vi drivs av att ge människor fler lätt tillgängliga möjligheter att förstå sin hälsa - så att de kan lämna den reaktiva vården och utvecklas mot ett mer proaktivt välbefinnande. Det är så vi bidrar till att förbättra livskvaliteten för varje individ och för hela samhället.